Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults

Abstract The therapeutic effects of B. coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B. coagulans Unique IS2 in the management of IBS symptoms in adults was invest...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ratna Sudha Madempudi, Jayesh J. Ahire, Jayanthi Neelamraju, Anirudh Tripathi, Satyavrat Nanal
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2e001c9759af472d86df199efb9057b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e001c9759af472d86df199efb9057b8
record_format	dspace
spelling	oai:doaj.org-article:2e001c9759af472d86df199efb9057b82021-12-02T16:08:16ZRandomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults10.1038/s41598-019-48554-x2045-2322https://doaj.org/article/2e001c9759af472d86df199efb9057b82019-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-48554-xhttps://doaj.org/toc/2045-2322Abstract The therapeutic effects of B. coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B. coagulans Unique IS2 in the management of IBS symptoms in adults was investigated. Patients (n = 153) fulfilling Rome III criteria were provided placebo capsules for a 2 weeks run-in period. Only patients satisfying compliance criteria (n = 136) were randomized (double blind) to receive either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points. Other clinical symptoms of IBS and serum cytokines were also evaluated. B. coagulans Unique IS2 showed significant improvement in primary and secondary endpoints, as compared to placebo. Haematology of both the arms remained normal. No significant changes in pro- (IL-6, IL-12, TNF-α, INF- γ) and anti-inflammatory cytokine (IL-10) levels were detected at the end of B. coagulans treatment (8 weeks) as compared to placebo. B. coagulans was well tolerated with no severe adverse events to report. Overall, the results demonstrate that B. coagulans Unique IS2 is efficacious in the management of IBS symptoms in adults (18–60 years).Ratna Sudha MadempudiJayesh J. AhireJayanthi NeelamrajuAnirudh TripathiSatyavrat NanalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ratna Sudha Madempudi Jayesh J. Ahire Jayanthi Neelamraju Anirudh Tripathi Satyavrat Nanal Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
description	Abstract The therapeutic effects of B. coagulans Unique IS2 have been well established in children with irritable bowel syndrome (IBS), but its efficacy in adults remain under reported. Thus, in this study the efficacy of B. coagulans Unique IS2 in the management of IBS symptoms in adults was investigated. Patients (n = 153) fulfilling Rome III criteria were provided placebo capsules for a 2 weeks run-in period. Only patients satisfying compliance criteria (n = 136) were randomized (double blind) to receive either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points. Other clinical symptoms of IBS and serum cytokines were also evaluated. B. coagulans Unique IS2 showed significant improvement in primary and secondary endpoints, as compared to placebo. Haematology of both the arms remained normal. No significant changes in pro- (IL-6, IL-12, TNF-α, INF- γ) and anti-inflammatory cytokine (IL-10) levels were detected at the end of B. coagulans treatment (8 weeks) as compared to placebo. B. coagulans was well tolerated with no severe adverse events to report. Overall, the results demonstrate that B. coagulans Unique IS2 is efficacious in the management of IBS symptoms in adults (18–60 years).
format	article
author	Ratna Sudha Madempudi Jayesh J. Ahire Jayanthi Neelamraju Anirudh Tripathi Satyavrat Nanal
author_facet	Ratna Sudha Madempudi Jayesh J. Ahire Jayanthi Neelamraju Anirudh Tripathi Satyavrat Nanal
author_sort	Ratna Sudha Madempudi
title	Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
title_short	Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
title_full	Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
title_fullStr	Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
title_full_unstemmed	Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
title_sort	randomized clinical trial: the effect of probiotic bacillus coagulans unique is2 vs. placebo on the symptoms management of irritable bowel syndrome in adults
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/2e001c9759af472d86df199efb9057b8
work_keys_str_mv	AT ratnasudhamadempudi randomizedclinicaltrialtheeffectofprobioticbacilluscoagulansuniqueis2vsplaceboonthesymptomsmanagementofirritablebowelsyndromeinadults AT jayeshjahire randomizedclinicaltrialtheeffectofprobioticbacilluscoagulansuniqueis2vsplaceboonthesymptomsmanagementofirritablebowelsyndromeinadults AT jayanthineelamraju randomizedclinicaltrialtheeffectofprobioticbacilluscoagulansuniqueis2vsplaceboonthesymptomsmanagementofirritablebowelsyndromeinadults AT anirudhtripathi randomizedclinicaltrialtheeffectofprobioticbacilluscoagulansuniqueis2vsplaceboonthesymptomsmanagementofirritablebowelsyndromeinadults AT satyavratnanal randomizedclinicaltrialtheeffectofprobioticbacilluscoagulansuniqueis2vsplaceboonthesymptomsmanagementofirritablebowelsyndromeinadults
_version_	1718384519515471872

Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults

Ejemplares similares